PURPOSE: Patients treated with chemoradiotherapy for locally advanced non-small-cell lung carcinoma (LA-NSCLC) were analyzed for local-regional failure (LRF) and overall survival (OS) with respect to radiotherapy dose intensity. METHODS AND MATERIALS: This study combined data from seven Radiation Therapy Oncology Group (RTOG) trials in which chemoradiotherapy was used for LA-NSCLC: RTOG 88-08 (chemoradiation arm only), 90-15, 91-06, 92-04, 93-09 (nonoperative arm only), 94-10, and 98-01. The radiotherapeutic biologically effective dose (BED) received by each individual patient was calculated, as was the overall treatment time-adjusted BED (tBED) using standard formulae. Heterogeneity testing was done with chi-squared statistics, and weighted pooled hazard ratio estimates were used. Cox and Fine and Gray's proportional hazard models were used for OS and LRF, respectively, to test the associations between BED and tBED adjusted for other covariates. RESULTS: A total of 1,356 patients were analyzed for BED (1,348 for tBED). The 2-year and 5-year OS rates were 38% and 15%, respectively. The 2-year and 5-year LRF rates were 46% and 52%, respectively. The BED (and tBED) were highly significantly associated with both OS and LRF, with or without adjustment for other covariates on multivariate analysis (p < 0.0001). A 1-Gy BED increase in radiotherapy dose intensity was statistically significantly associated with approximately 4% relative improvement in survival; this is another way of expressing the finding that the pool-adjusted hazard ratio for survival as a function of BED was 0.96. Similarly, a 1-Gy tBED increase in radiotherapy dose intensity was statistically significantly associated with approximately 3% relative improvement in local-regional control; this is another way of expressing the finding that the pool-adjusted hazard ratio as a function of tBED was 0.97. CONCLUSIONS: Higher radiotherapy dose intensity is associated with improved local-regional control and survival in the setting of chemoradiotherapy.
PURPOSE:Patients treated with chemoradiotherapy for locally advanced non-small-cell lung carcinoma (LA-NSCLC) were analyzed for local-regional failure (LRF) and overall survival (OS) with respect to radiotherapy dose intensity. METHODS AND MATERIALS: This study combined data from seven Radiation Therapy Oncology Group (RTOG) trials in which chemoradiotherapy was used for LA-NSCLC: RTOG 88-08 (chemoradiation arm only), 90-15, 91-06, 92-04, 93-09 (nonoperative arm only), 94-10, and 98-01. The radiotherapeutic biologically effective dose (BED) received by each individual patient was calculated, as was the overall treatment time-adjusted BED (tBED) using standard formulae. Heterogeneity testing was done with chi-squared statistics, and weighted pooled hazard ratio estimates were used. Cox and Fine and Gray's proportional hazard models were used for OS and LRF, respectively, to test the associations between BED and tBED adjusted for other covariates. RESULTS: A total of 1,356 patients were analyzed for BED (1,348 for tBED). The 2-year and 5-year OS rates were 38% and 15%, respectively. The 2-year and 5-year LRF rates were 46% and 52%, respectively. The BED (and tBED) were highly significantly associated with both OS and LRF, with or without adjustment for other covariates on multivariate analysis (p < 0.0001). A 1-Gy BED increase in radiotherapy dose intensity was statistically significantly associated with approximately 4% relative improvement in survival; this is another way of expressing the finding that the pool-adjusted hazard ratio for survival as a function of BED was 0.96. Similarly, a 1-Gy tBED increase in radiotherapy dose intensity was statistically significantly associated with approximately 3% relative improvement in local-regional control; this is another way of expressing the finding that the pool-adjusted hazard ratio as a function of tBED was 0.97. CONCLUSIONS: Higher radiotherapy dose intensity is associated with improved local-regional control and survival in the setting of chemoradiotherapy.
Authors: Mitchell Machtay; Chuanchieh Hsu; Ritsuko Komaki; William T Sause; R Suzanne Swann; Corey J Langer; Roger W Byhardt; Walter J Curran Journal: Int J Radiat Oncol Biol Phys Date: 2005-05-31 Impact factor: 7.038
Authors: Chandra P Belani; Hak Choy; Phil Bonomi; Charles Scott; Patrick Travis; John Haluschak; Walter J Curran Journal: J Clin Oncol Date: 2005-08-08 Impact factor: 44.544
Authors: C A Perez; T F Pajak; P Rubin; J R Simpson; M Mohiuddin; L W Brady; R Perez-Tamayo; M Rotman Journal: Cancer Date: 1987-06-01 Impact factor: 6.860
Authors: Everett E Vokes; James E Herndon; Michael J Kelley; M Giulia Cicchetti; Nithya Ramnath; Harvey Neill; James N Atkins; Dorothy M Watson; Wallace Akerley; Mark R Green Journal: J Clin Oncol Date: 2007-04-02 Impact factor: 44.544
Authors: K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: H Choy; R F Devore; K R Hande; L L Porter; P Rosenblatt; F Yunus; L Schlabach; C Smith; Y Shyr; D H Johnson Journal: Int J Radiat Oncol Biol Phys Date: 2000-07-01 Impact factor: 7.038
Authors: Mark A Socinski; A William Blackstock; Jeffrey A Bogart; Xiaofei Wang; Michael Munley; Julian Rosenman; Lin Gu; Gregory A Masters; Peter Ungaro; Arthur Sleeper; Mark Green; Antonius A Miller; Everett E Vokes Journal: J Clin Oncol Date: 2008-05-20 Impact factor: 44.544
Authors: Marie Wanet; Antoine Delor; François-Xavier Hanin; Benoît Ghaye; Aline Van Maanen; Vincent Remouchamps; Christian Clermont; Samuel Goossens; John Aldo Lee; Guillaume Janssens; Anne Bol; Xavier Geets Journal: Strahlenther Onkol Date: 2017-07-21 Impact factor: 3.621
Authors: Yucel Altundal; Gizem Cifter; Alexandre Detappe; Erno Sajo; Panagiotis Tsiamas; Piotr Zygmanski; Ross Berbeco; Robert A Cormack; Mike Makrigiorgos; Wilfred Ngwa Journal: Phys Med Date: 2014-12-06 Impact factor: 2.685